92 related articles for article (PubMed ID: 30226612)
41. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin α
Kuo TC; Wu MH; Yang SH; Chen ST; Hsu TW; Jhuang JY; Liao YY; Tien YW; Huang MC
Oncogene; 2021 Feb; 40(7):1242-1254. PubMed ID: 33420364
[TBL] [Abstract][Full Text] [Related]
42. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
43. Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer.
Onishi H; Kai M; Odate S; Iwasaki H; Morifuji Y; Ogino T; Morisaki T; Nakashima Y; Katano M
Cancer Sci; 2011 Jun; 102(6):1144-50. PubMed ID: 21338440
[TBL] [Abstract][Full Text] [Related]
44. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
Chang W; Liu M; Xu J; Fu H; Zhou B; Yuan T; Chen P
Tumour Biol; 2016 Nov; 37(11):14813-14824. PubMed ID: 27638830
[TBL] [Abstract][Full Text] [Related]
45. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer.
Koltai T; Reshkin SJ; Carvalho TMA; Cardone RA
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921242
[TBL] [Abstract][Full Text] [Related]
46. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
[TBL] [Abstract][Full Text] [Related]
47. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
48. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway.
Huang XY; Wang HC; Yuan Z; Huang J; Zheng Q
Hepatogastroenterology; 2012 May; 59(115):889-93. PubMed ID: 22020907
[TBL] [Abstract][Full Text] [Related]
49. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
[TBL] [Abstract][Full Text] [Related]
50. Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma.
Sui C; Zhuang C; Sun D; Yang L; Zhang L; Song L
Oncotarget; 2017 Jul; 8(28):45837-45847. PubMed ID: 28507277
[TBL] [Abstract][Full Text] [Related]
51. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
[TBL] [Abstract][Full Text] [Related]
52. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
[TBL] [Abstract][Full Text] [Related]
53. Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells.
Zhang WW; Zhan SH; Geng CX; Sun X; Erkan M; Kleeff J; Xie XJ
Mol Med Rep; 2016 Oct; 14(4):3627-33. PubMed ID: 27573419
[TBL] [Abstract][Full Text] [Related]
54. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA.
He X; Zheng Z; Li J; Ben Q; Liu J; Zhang J; Ji J; Yu B; Chen X; Su L; Zhou L; Liu B; Yuan Y
Carcinogenesis; 2012 Mar; 33(3):555-62. PubMed ID: 22223849
[TBL] [Abstract][Full Text] [Related]
55. Regulation of pancreatic stellate cell activation by Notch3.
Song H; Zhang Y
BMC Cancer; 2018 Jan; 18(1):36. PubMed ID: 29304760
[TBL] [Abstract][Full Text] [Related]
56. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
Zhao G; Qin Q; Zhang J; Liu Y; Deng S; Liu L; Wang B; Tian K; Wang C
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S301-11. PubMed ID: 22552606
[TBL] [Abstract][Full Text] [Related]
57. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
58. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma.
Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J
Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693
[TBL] [Abstract][Full Text] [Related]
60. Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma.
Cai ZZ; Xu LB; Cai JL; Wang JS; Zhou B; Hu H
Genet Mol Res; 2015 Mar; 14(1):2707-15. PubMed ID: 25867419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
